Supplements Company Sued Over False Advertising lawstreetmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lawstreetmedia.com Daily Mail and Mail on Sunday newspapers.
email article
Thirteen new rare gene variants in loci related to synaptic function and neuronal development were associated with Alzheimer s disease.
(Alzheimer s and Dementia)
In an unusual
JAMA op-ed, three members of the FDA s advisory committee reviewing aducanumab took another shot at the controversial Alzheimer s drug candidate, laying out reasons why aducanumab shouldn t be approved.
The FDA rejected Acadia Pharmaceuticals bid to expand indications for pimavanserin (Nuplazid) to include hallucinations and delusions associated with dementia-related psychosis. The notice came a month after the agency first alerted the company to potential snags with its application.
Approved: viloxazine extended-release capsules (Qelbree), a non-stimulant ADHD treatment for children ages 6 to 17 and the first new drug for the disorder in over a decade, Supernus Pharmaceuticals said.
(Nature Communications)
People with a previous rheumatoid arthritis diagnosis had a 30% to 50% lower risk of later developing Parkinson s, a nested case-control study showed.
(Journal of Parkinson s Disease)
(Movement Disorders)
(New York Times)
(Alzheimer s and Dementia)
Medicare data showed that payments for neurologist-prescribed brand name drugs jumped 50% from 2013 to 2017, but claims for these drugs rose only 8%. (Neurology)
(JAMA Network Open)
Military veterans with psychogenic or epileptic seizures had higher risks for death by suicide and suicide-related behavior than the general veteran population.
(Neurology Clinical Practice)
Silencing a gene involved in pain signaling reduced pain sensitivity in animal models and reversed chemotherapy-induced chronic pain in mice. (
Dr. Sy will help advance neurological care for Manhattan residents by developing a comprehensive neurocritical care program
Heustein Lu Sy, MD, has been appointed director of neurosurgical critical care at Lenox Hill Hospital. Over the past four years, Dr. Sy has served as an attending neurointensivist at the hospital’s department of neurosurgery.
In his new role, Dr. Sy will be responsible for developing a comprehensive, interdisciplinary and integrative clinical neurocritical care program. In addition, Dr. Sy will provide leadership in meeting the hospital’s service excellence initiatives by implementing quality standards for neurocritical care; guide the educational needs of the neurocritical care team; and promote a culture of innovation, improving neurocritical care research.